The development of exceptionally potent inhibitors of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid and vanilloid receptors), is detailed. With the help of an extensive set of collaborations that will provide not only the in vitro characterization of the inhibitors, but also their in vivo evaluation (animal pain, sleep, anxiety, and multiple sclerosis models) and characterization (PK properties, metabolism), the studies will clarify the role of endogenous oleamide and anandamide, establish the utility of FAAH as a therapeutic target, and potentially provide therapeutic agents for the treatment of sleep disorders, anxiety, epilepsy, pain, cancer, Parkinson's and Huntington's disease, stroke, and/or multiple sclerosis. Preliminary studies conducted over a period spanning 5 years have been extensive, providing the first class of exceptionally potent, competitive inhibitors of FAAH and defining key structural features that impact future inhibitor design. These studies have provided a set of a-ketoheterocycle FAAH inhibitors with Ki's that drop below 200 pM and that are l00-1000 times more potent than the corresponding trifluoromethyl ketones.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015648-04
Application #
6915469
Study Section
Special Emphasis Panel (ZRG1-SSS-B (01))
Program Officer
Rapaka, Rao
Project Start
2002-09-30
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$231,500
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Kornahrens, Anne F; Cognetta 3rd, Armand B; Brody, Daniel M et al. (2017) Design of Benzoxathiazin-3-one 1,1-Dioxides as a New Class of Irreversible Serine Hydrolase Inhibitors: Discovery of a Uniquely Selective PNPLA4 Inhibitor. J Am Chem Soc 139:7052-7061
Boger, Dale L (2017) The Difference a Single Atom Can Make: Synthesis and Design at the Chemistry-Biology Interface. J Org Chem 82:11961-11980
Burman, Michael A; Szolusha, Kerribeth; Bind, Rebecca et al. (2016) FAAH inhibitor OL-135 disrupts contextual, but not auditory, fear conditioning in rats. Behav Brain Res 308:1-5
Janssen, Freek J; Baggelaar, Marc P; Hummel, Jessica J A et al. (2015) Comprehensive Analysis of Structure-Activity Relationships of ?-Ketoheterocycles as sn-1-Diacylglycerol Lipase ? Inhibitors. J Med Chem 58:9742-53
Otrubova, Katerina; Srinivasan, Venkat; Boger, Dale L (2014) Discovery libraries targeting the major enzyme classes: the serine hydrolases. Bioorg Med Chem Lett 24:3807-13
Duncan, Katharine K; Otrubova, Katerina; Boger, Dale L (2014) ?-Ketoheterocycle inhibitors of fatty acid amide hydrolase: exploration of conformational constraints in the acyl side chain. Bioorg Med Chem 22:2763-70
Otrubova, Katerina; Cravatt, Benjamin F; Boger, Dale L (2014) Design, synthesis, and characterization of ?-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase. J Med Chem 57:1079-89
Otrubova, Katerina; Brown, Monica; McCormick, Michael S et al. (2013) Rational design of fatty acid amide hydrolase inhibitors that act by covalently bonding to two active site residues. J Am Chem Soc 135:6289-99
Booker, Lamont; Kinsey, Steven G; Abdullah, Rehab A et al. (2012) The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 165:2485-96
Otrubova, Katerina; Boger, Dale L (2012) ?-Ketoheterocycle-based Inhibitors of Fatty Acid Amide Hydrolase (FAAH). ACS Chem Neurosci 3:340-348

Showing the most recent 10 out of 28 publications